Median days of follow-up, number of events, crude incidence rate per 100 person years and hazard ratio of effectiveness and safety outcomes in new users of dabigatran, rivaroxaban or apixaban compared to warfarin for non-valvular atrial fibrillation.
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://figshare.com/articles/dataset/Median_days_of_follow-up_number_of_events_crude_incidence_rate_per_100_person_years_and_hazard_ratio_of_effectiveness_and_safety_outcomes_in_new_users_of_dabigatran_rivaroxaban_or_apixaban_compared_to_warfarin_for_non-valvular_atrial_fibril/9732209
下载链接
链接失效反馈官方服务：
资源简介：
Median days of follow-up, number of events, crude incidence rate per 100 person years and hazard ratio of effectiveness and safety outcomes in new users of dabigatran, rivaroxaban or apixaban compared to warfarin for non-valvular atrial fibrillation.
创建时间：
2019-08-26
